UPDATE 1-Repros halts dosing of lead drug; seeks funding

* Says considering various financial alternatives

* If unable to get funding, may explore sale

* Suspends dosing of proellex in all ongoing trials

* Shares fall 60 pct in pre-market trade

Aug 3 (Reuters) - Repros Therapeutics (RPRX.O) voluntarily suspended dosing patients in all clinical trials with its lead drug proellex and said it is considering various financing alternatives to address its immediate short-term liquidity needs, sending its shares down more than 60 percent.

Repros said if it is unable to obtain adequate financing to meet its immediate short term liquidity needs, it will pursue other options, including sale of the company or assets, a bankruptcy filing or liquidation.

The company said it suspended dosing "in the interest of patient safety", after the occurrence of clinically significant increases in liver enzymes.

Proellex was being studied in trials for treatment of chronic symptomatic uterine fibroids, anemia associated with this condition, and endometriosis.

The company will have a meeting in late September with U.S. Food and Drug Administration about the safety of proellex and overall direction and scope of the program, it said.

Of the nine patients who had an increase in liver enzymes, seven were severe enough elevations to be reported to the FDA as serious adverse events.

Shares of Repros fell 60 percent to $1.02 in trading before the bell. (Reporting by Jennifer Robin Raj in Bangalore; Editing by Gopakumar Warrier)